Compound Codex
Independent evidence record Peptides & research compounds Join the discussion →

← All guides

Reference

Routes of Administration, Explained

4 min read

Peptides are fragile molecules, and how they enter the body largely determines whether they reach the bloodstream intact. This guide explains the main routes of administration and the concept—bioavailability—that ties them together. It is educational only: no doses, protocols, or injection technique.

What “bioavailability” means

Bioavailability is the fraction of an administered dose that reaches the systemic circulation in active form. By convention, an intravenous (IV) dose is defined as 100% bioavailable, because it is placed directly into the blood. Every other route is measured against that benchmark and is usually lower, because the drug must survive absorption and, for some routes, a first pass through the liver before reaching circulation.

It is denoted F (or as a percentage). Two things determine it: the rate of absorption and the extent. For peptides—chains of amino acids that the body is built to digest—the “extent” is where most routes run into trouble.

Subcutaneous injection: the default for most peptides

Most therapeutic and research peptides are injected subcutaneously (into the fat layer under the skin) for a simple reason: it bypasses the digestive tract. The subcutaneous space is well supplied with capillaries and lymphatic vessels but lacks the harsh enzymatic environment of the gut, so peptides are absorbed comparatively intact—often in the rough range of roughly 65–100%, depending on the molecule.

Absorption is not instantaneous. The injection forms a small depot from which the peptide diffuses gradually, producing a slower, lower, more sustained blood-level curve than an IV dose. Some peptides are partly degraded by enzymes at the injection site, and absorption can vary with the site used—a reminder that “subcutaneous” is reliable but not perfectly uniform.

Oral: why most peptides barely make it

Swallowing a peptide is convenient but, for most, ineffective. The gastrointestinal tract is a hostile environment: stomach acid (pH ~1–2) plus digestive enzymes such as pepsin, trypsin, and chymotrypsin break peptides into fragments and amino acids, and the intestinal wall poorly absorbs large, water-loving molecules. The result is inherent oral bioavailability typically below 1% for unmodified peptides—sometimes well under that.

There are notable exceptions, and they show the engineering required to beat the gut. Oral semaglutide (Rybelsus) is co-formulated with the absorption enhancer SNAC, achieving only roughly 1% bioavailability—workable only because the drug is extraordinarily potent and long-lived. Oral octreotide (Mycapssa, FDA-approved 2020) uses a separate “transient permeability enhancer” technology. These are exceptions that prove the rule, not evidence that peptides are generally orally active.

Intranasal and topical: niche routes

The nasal lining is thin, vascular, and bypasses first-pass liver metabolism, making it viable for a few small peptides—desmopressin and salmon calcitonin nasal sprays have been used clinically for years. But nasal absorption falls off sharply as size increases; marketed nasal peptides top out in the low-kilodalton range (salmon calcitonin, the largest, is ~3.4 kDa), so injection remains standard for larger peptides.

Topical (on the skin) delivery faces an even stiffer barrier. The stratum corneum blocks most molecules over about 500 daltons—the widely cited “500-dalton rule”—and common cosmetic peptides (e.g., palmitoyl pentapeptide-4 at ~800 Da, acetyl hexapeptide-8 at ~890 Da) exceed it. Without specialized delivery systems, such peptides largely act at or near the skin surface rather than entering the bloodstream.

Bottom line

Route of administration is not a detail—it dictates whether a peptide works at all. Injection persists as the default because peptides are built to be digested, and the gut, skin, and even the nose are formidable barriers. Oral, nasal, and topical peptide products exist only where the molecule is small or potent enough, or where formulation chemistry overcomes the barrier. This is general education, not medical advice; legal status, sourcing, and safety vary widely, and any use should be discussed with a qualified clinician.

Sources

Discussion

Per the house rules — evidence over anecdote, no sourcing, no dosing protocols. Comments are reviewed before they appear.

Loading…